Allo CD7 CAR WU-CART-007

Allo CD7 CAR WU-CART-007

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description

The purpose of this study is to determine thesafety and tolerability of an experimental form of therapy, known as WU-CART-007(“study drug”).  WU-CART-007 uses immunecells, called T cells, that are genetically changed to identify cancer cells.In this study, T cells are collected from a healthy human donor and have beenmodified in a laboratory. If the genetically changed T cells recognize andattach to cancer cells, they may have the ability to kill those cancer cells.

Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) orLymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or hasnot responded to treatment (refractory) may be eligible for the study.

Eligibility and criteria
IRB Number:
21-019423
Eligible age range:
12 years - 30 years
Clinical trial phase:
Phase I
Phase II
Official title:
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

What to expect

As a participant in the research you will:

  • Receive a study drug WU-CART-007
  • Avoid taking certain medications (steroids,chemotherapy agents)
  • Stay in the hospital for at least 7 days afterreceiving the study drug
  • Complete follow up visits
  • Have research blood samples drawn
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.